De Angelis, C., Bruzzese, D., Bernardo, A., Baldini, E., Leo, L., Fabi, A., . . . Arpino, G. (2021). Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: A multicenter, phase II, single arm trial (GIM11-BERGI). ESMO Open.
Citação norma ChicagoDe Angelis, C., et al. "Eribulin in Combination With Bevacizumab As Second-line Treatment for HER2-negative Metastatic Breast Cancer Progressing After First-line Therapy With Paclitaxel and Bevacizumab: A Multicenter, Phase II, Single Arm Trial (GIM11-BERGI)." ESMO Open 2021.
Citação norma MLADe Angelis, C., et al. "Eribulin in Combination With Bevacizumab As Second-line Treatment for HER2-negative Metastatic Breast Cancer Progressing After First-line Therapy With Paclitaxel and Bevacizumab: A Multicenter, Phase II, Single Arm Trial (GIM11-BERGI)." ESMO Open 2021.